WHO ICTRP trial
Individualisation of management with novel upfront therapy enzalutamide in newly…
NL-OMON51572 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON51572 |
|---|---|
| Public title | Individualisation of management with novel upfront therapy enzalutamide in newly diagnosed metastasized prostate cancer using (PSMA)PET/CT imaging |
| Scientific title | Individualisation of management with novel upfront therapy enzalutamide in newly diagnosed metastasized prostate cancer using (PSMA)PET/CT imaging - PET-MaN-enza |
| Primary sponsor | Universitair Medisch Centrum Utrecht |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Observational invasive |
| Countries | The Netherlands |
| Conditions | Prostate cancer; Malignancy of the prostate;10027656;10018188;10036958;Prostate cancer; Malignancy of the prostate |
| Interventions | ;Metastastasis;Prostate cancer;PSMA-PET/CT;Upfront therapy enzalutamide |
| Registration date | Nov 29, 2022 |
| Target size | 150 |
| Secondary IDs | NCT05539300;NL81959.041.22 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: